Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

Scientists have developed a new way to use information from your genes or proteins to help doctors diagnose or treat diseases ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Alzheimer’s disease, the most common form of dementia affecting more than three million Americans a year, has proven difficult to diagnose in earlier stages. But detecting and treating the condition ...

House Bill 8, has been introduced in Ohio with the goal of expanding private insurance and Medicaid coverage for biomarker ...

Kettering, is hoping the third time's the charm on her effort to require private insurers to cover "biomarker" medical testing and thereby improve health outcomes in Ohio and cut down on personal ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Researchers have developed a test that spots early signs of Alzheimer's disease. Rather than looking for amyloid-beta plaques ...

“In my opinion,” he continued, “any future diagnostic test derived from biomarkers must include robust counseling and education to ensure people understand the test’s limitations and the ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...

A cerebrospinal fluid biomarker test can detect early Alzheimer's pathology by identifying small amounts of clumping-prone tau protein and its misfolded forms, years before they appear on brain scans.